Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (291-300 of 338) with videos related to

Pageof 34
Sort By:
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 TherapyJiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic CancerYves Boucher, Jessica M Posada, Sonu Subudhi, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Ecancermedicalscience|December 21, 2016
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, MumbaiPan Pantziarka, Lisa Hutchinson, Nicolas André, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomasSam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Pageof 34

Showing results (291-300 of 338) with videos related to

Sort By:
Pageof 34
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 TherapyJiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic CancerYves Boucher, Jessica M Posada, Sonu Subudhi, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Ecancermedicalscience|December 21, 2016
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, MumbaiPan Pantziarka, Lisa Hutchinson, Nicolas André, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomasSam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Pageof 34